Canadian researchers close in on new treatments for type 2 diabetes

	Tweet

Researchers funded by the Canadian Institutes of Health Research (CIHR) and the Canadian Diabetes Association (CDA) have identified an unsuspected role of a protein named SHP-1 that could constitute a new therapeutic path against Type 2 Diabetes.

Under the direction of professor Andri Marette (Laval University), Nicole Beauchemin (McGill University), Martin Oliver (McGill University Health Centre) and Katherine Siminovitch (University of Toronto) were part of a Canadian and American team which published an article in the May issue of Nature Medicine that explains the role of SHP-1 in the control of blood glucose.

The researchers already knew that SHP-1 played a role in regulating the immune system.

Canadian and American researchers did, thanks to a series of mutant or genetically modified mice producing little or no SHP-1.

“Our results indicate that these mice are extremely sensitive to insulin and, consequently, they are very effective in metabolising glucose at the level of the liver and the muscles,” notes Andri Marette. In addition, the researchers highlighted that SHP-1 inhibits the decomposition of insulin by the liver. “This could explain the increase in the insulin concentrations of certain metabolic disorders associated with obesity,” indicates the researcher.

“The results of Andre Marette and his team represent an important step in the development of a new therapeutic approach in the fight against diabetes. Advances in the treatment of diabetes are needed to improve the lives of the more than two million Canadians already affected by it and the many more who will develop the disease in the years to come. The study is a perfect example of the potential benefits of investing in health research,” says Dr. Diane Finegood, based in Vancouver and Scientific Director of the CIHR Institute of Nutrition, Metabolism and Diabetes.

“By inhibiting the activity of SHP-1, it would perhaps be possible to restore better control of blood glucose,” suggests professor Marette. The difficulty, however, is to reach that point without blocking the essential part played by this protein in the immune system. The SHP-1 protein is present in humans, but its role in the regulation of the metabolism of glucose and in the development of Type 2 Diabetes remains to be shown.

“Good glucose control is essential for managing diabetes and preventing the debilitating complications associated with diabetes,” says Dr. Paula Dworatzek, Senior Research Associate, Canadian Diabetes Association. “We congratulate Dr. Marette and his team for these initial findings, which will pave the way for his team and others to pursue a potential new therapy in the management of diabetes.”

http://www.cihr-irsc.gc.ca/

RELATED STORIES:
Phone contact with nurses linked with better outcomes for women with gestational diabetes   Death rate drops among Americans with diabetes -CDC   Correct treatment of common diabetic foot infections can reduce amputations   “Pre-diabetes,” diabetes rising among U.S. teens   Experimental bariatric surgery controls blood sugar in rats with diabetes   53 millions Americans might develop diabetes by 2025   New inflammation hormone link may pave way to study new drugs for type 2 diabetes   Diabetic retinopathy research could reduce screening costs   Liver fat gets a wake-up call that maintains blood sugar levels   Low testosterone levels could raise diabetes risk for men   Prosthetic lets diabetic get a foot up on life   Dealing with Diabetes, One Patient at a Time

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]